Impel Pharmaceuticals Inc. is a Seattle-based commercial-stage biopharmaceutical company that is dedicated to developing innovative therapies for diseases with high unmet medical needs. They utilize their proprietary Precision Olfactory Delivery (POD) technology to optimize drug delivery and provide transformative treatments. Their flagship product, Trudhesa, is a dihydroergotamine mesylate nasal spray that has been approved for the acute treatment of migraine in adults. Impel Pharmaceuticals actively seeks collaborations and partnerships to explore the therapeutic potential of their technology with both small and large molecules.
With a focus on the upper nasal space, Impel Pharmaceuticals aims to achieve more rapid and consistent bioavailability and clinical response through their injection-like absorption approach. They are disruptors in the field, striving to create life-changing therapies and improve patient outcomes. Through their commitment to innovation and their dedication to addressing unmet medical needs, Impel Pharmaceuticals is poised to make a significant impact in the pharmaceutical industry.
Generated from the website